Skip to main
  1. Stocks
  2. Sophia Genetics SA
  3. Forecast
SOPH

SOPH Stock Forecast & Price Target

SOPH Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Sophia Genetics is attractive fundamentally because its cloud-based, pay-per-analysis SaaS model converts increasingly complex multimodal genomic data into recurring high-margin revenue without owning lab infrastructure, while adjusted gross margin reached 74.2% in 2025 and 75.4% in 1Q26. Its moat is reinforced by a compounding global network of roughly 1,000 hospitals and laboratories across 75 countries, more than 2.5 million genomic profiles, and strong retention metrics including 117% net dollar retention and below-1% annualized churn. The bullish case is further supported by 2025 revenue of $77.3M, 2026 guidance of $92M–$96M, large U.S. health-system wins, and improving BioPharma momentum through partnerships such as AstraZeneca, Johnson & Johnson, and Myriad Genetics.

Bears say

Sophia Genetics is challenged by weak fundamental profitability and uneven monetization, as 2024 revenue growth was just 4% despite 11% volume growth, implying a 6-7% decline in revenue per analysis amid biopharma headwinds. Its future depends heavily on scaling the SOPHiA DDM Platform and newer liquid-biopsy products, but with only about 100 MSK-ACCESS and MSK-IMPACT customers combined and roughly half of liquid-biopsy accounts still in implementation as of 1Q26, commercialization remains unproven. Competitive, cybersecurity, legal, and dilution risks also weigh on the outlook, especially because the company is not yet profitable and may need additional capital that could dilute shareholders.

SOPH has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sophia Genetics SA and is not a guaranteed prediction by Public.com or investment advice.

SOPH Analyst Forecast & Price Prediction

Get the latest SOPH stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in SOPH

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sophia Genetics SA (SOPH) Forecast

Analysts have given SOPH a Strong Buy based on their latest research and market trends.

According to 3 analysts, SOPH has a Strong Buy consensus rating as of Oct 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sophia Genetics SA (SOPH)


SOPH Analyst Forecast & Price Prediction

Get the latest SOPH stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in SOPH

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover SOPH stock data and trends